Dr. Zell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Hematology/Oncology, UC Irvine Med Center
101 The City Dr South
Orange, CA 92868Phone+1 714-456-5153Fax+1 714-456-2242
Summary
- Dr. Jason Zell is an oncologist in Orange, CA and is affiliated with UCI Medical Center. He received his medical degree from Nova Southeastern University - College of Osteopathic Medicine and has been in practice 16 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in hematologic oncology, clinical research, gastrointestinal oncology, and clinical trials.
Education & Training
University of California (Irvine)Fellowship, Hematology and Medical Oncology, 2003 - 2007- University of California (Irvine)Residency, Internal Medicine, 2001 - 2003
Nova Southeastern University College of Osteopathic MedicineClass of 2001
Certifications & Licensure
CA State License 2002 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Physician of Excellence Orange County Medical Association, 2014-2023
- Super Doctors, Rising Star - Los Angeles www.superdoctors.com
- Cancer Clinical Investigator Team Leadership Award National Institutes of Health, National Cancer Institute
- Join now to see all
Clinical Trials
- Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jun 01
- Trial of Aspirin and Arginine Restriction in Colorectal Cancer Start of enrollment: 2008 Sep 24
- Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma Start of enrollment: 2008 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 110 citationsAsian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.Sai-Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell
Journal of Thoracic Oncology. 2009-09-01 - 231 citationsNatural History of Stage I Non-Small Cell Lung Cancer: Implications for Early DetectionDan J. Raz, Jason A. Zell, S-H. Ignatius Ou, David R. Gandara, Hoda Anton-Culver
Chest. 2007-07-01 - 202 citationsctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.Arvind Dasari, Van K. Morris, Carmen J. Allegra, Chloe E. Atreya, Al B. Benson
Nature Reviews. Clinical Oncology. 2020-07-06
Books/Book Chapters
Press Mentions
Beating Cancer – One Patient at a TimeFebruary 23rd, 2020
University of California (Irvine) Hematology Oncology FellowshipMay 5th, 2017
Past Colon Cancer Tied to Future Cancer RisksJuly 15th, 2013- Join now to see all
Grant Support
- Risk Reduction Through Polyamine Inhibition Among Colorectal Carcinoma PatientsNational Cancer Institute2009–2011
- Phase IIA Clinical Biomarker Trial Of Aspirin And Arginine Restriction In ColonNational Center For Research Resources2010
Committees
- Chair, The Hope Foundation/Dr. Charles Coltman Fellowship Award Committee 2013 - Present
- Section Editor, Gastrointestinal Oncology, Editorial Board, Journal of Adolescent and Young Adult Oncology 2010 - Present
- Associate Editor, Editorial Board, Journal of Carcinogenesis 2010 - 2013
Professional Memberships
- Member
- Member
- Member
- Member
External Links
- Clinical Profilehttp://www.ucirvinehealth.org/find-a-doctor/z/jason-zell/
- Academic Profilehttp://www.faculty.uci.edu//profile.cfm?faculty_id=5483
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
